LifeMD, Inc. (NASDAQ:LFMD) Short Interest Up 27.5% in March

LifeMD, Inc. (NASDAQ:LFMD) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 8,160,000 shares, an increase of 27.5% from the February 28th total of 6,400,000 shares. Based on an average trading volume of 1,150,000 shares, the short-interest ratio is currently 7.1 days. Currently, 23.6% of the shares of the company are short sold.

Insider Transactions at LifeMD

In other LifeMD news, CEO Justin Schreiber sold 25,000 shares of LifeMD stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $5.19, for a total value of $129,750.00. Following the completion of the sale, the chief executive officer now owns 2,703,715 shares in the company, valued at $14,032,280.85. The trade was a 0.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Jessica Friedeman sold 30,000 shares of the business’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $5.66, for a total transaction of $169,800.00. Following the completion of the sale, the chief marketing officer now directly owns 170,000 shares of the company’s stock, valued at $962,200. This represents a 15.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 105,000 shares of company stock worth $677,050 over the last quarter. Company insiders own 15.97% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Intech Investment Management LLC bought a new position in shares of LifeMD during the third quarter worth about $54,000. MetLife Investment Management LLC boosted its stake in shares of LifeMD by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 21,138 shares of the company’s stock valued at $111,000 after purchasing an additional 11,910 shares during the last quarter. Centiva Capital LP bought a new position in LifeMD during the third quarter worth $196,000. State Street Corp boosted its position in LifeMD by 20.0% during the third quarter. State Street Corp now owns 1,155,495 shares of the company’s stock valued at $6,055,000 after acquiring an additional 192,861 shares during the last quarter. Finally, XTX Topco Ltd grew its holdings in LifeMD by 306.8% during the 3rd quarter. XTX Topco Ltd now owns 55,738 shares of the company’s stock worth $292,000 after acquiring an additional 42,037 shares during the period. 35.52% of the stock is owned by institutional investors and hedge funds.

LifeMD Price Performance

LFMD stock traded up $0.18 during midday trading on Wednesday, reaching $5.61. 447,804 shares of the stock were exchanged, compared to its average volume of 804,577. The company has a fifty day moving average price of $5.85 and a 200 day moving average price of $5.44. LifeMD has a 52 week low of $3.99 and a 52 week high of $12.88. The stock has a market capitalization of $250.12 million, a PE ratio of -8.77 and a beta of 1.50.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings data on Monday, March 10th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02. The business had revenue of $64.26 million during the quarter, compared to the consensus estimate of $57.43 million. As a group, analysts anticipate that LifeMD will post -0.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LFMD has been the topic of several analyst reports. HC Wainwright increased their target price on LifeMD from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, March 12th. KeyCorp reduced their price objective on shares of LifeMD from $10.00 to $7.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. B. Riley upgraded shares of LifeMD to a “strong-buy” rating in a research report on Tuesday, March 11th. Mizuho started coverage on shares of LifeMD in a research report on Wednesday, December 4th. They set a “neutral” rating and a $7.00 price target on the stock. Finally, Lake Street Capital started coverage on shares of LifeMD in a research report on Tuesday, December 10th. They set a “buy” rating and a $12.00 price objective for the company. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $11.43.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.